|
1
|
Xie D, Gore C, Zhou J, Ponga RC, Zhang HF,
Yu LY, Vessellad RL, Min W and Hsieh JT: DAB2IP coordinates both
PI3K-Akt and ASK1 pathways for cell survival and apoptosis. Proc
Natl Acad Sci USA. 106:19878–19883. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhang X, Li N, Li X, Zhao W, Qiao Y, Liang
L and Ding Y: Low expression of DAB2IP contributes to malignant
development and poor prognosis in hepatocellular carcinoma. J
Gastroenterol Hepatol. 27:1117–1125. 2012. View Article : Google Scholar
|
|
3
|
Kong Z, Xie D, Boike T, Raghavan P, Burma
S, Chen DJ, Habib AA, Chakraborty A, Hsieh JT and Saha D:
Downregulation of human DAB2IP gene expression in prostate cancer
cells results in resistance to ionizing radiation. Cancer Res.
70:2829–2839. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wu K, Xie D, Zou Y, Zhang T, Pong RC, Xiao
G, Fazli L, Gleave M, He D, Boothman DA and Hsieh JT: The mechanism
of DAB2IP in chemoresistance of prostate cancer cells. Clin Cancer
Res. 19:4740–4749. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yun EJ, Beak ST, Xie D, Tseng SF, Dobin T,
Hernandez E, Zhou J, Zhang L, Yang J, Sun H, et al: DAB2IP
regulates cancer stem cell phenotypes through modulating stem cell
factor receptor and ZEB1. Oncogene. 34:2741–2752. 2015. View Article : Google Scholar
|
|
6
|
Wadas TJ, Pandya DN, Solingapuram Sai KK
and Mintz A: Molecular targeted α-particle therapy for oncologic
applications. Am J Roentgenol. 203:253–260. 2014. View Article : Google Scholar
|
|
7
|
Baidoo KE, Yong K and Brechbiel MW:
Molecular pathways: Targeted α-particle radiation therapy. Clin
Cancer Res. 19:530–537. 2013. View Article : Google Scholar
|
|
8
|
El-Amm J and Aragon-Ching JB: Radium-223
for the treatment of castration-resistant prostate cancer. Onco
Targets Ther. 8:1103–1109. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wissing MD, van Leeuwen FW, van der Pluijm
G and Gelderblom H: Radium-223 chloride: Extending life in prostate
cancer patients by treating bone metastases. Clin Cancer Res.
19:5822–5827. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Abbas N, Heyerdahl H, Bruland OS, Borrebak
J, Nesland J and Dahle J: Experimental α-particle
radioimmunotherapy of breast cancer using 227Th-labeled
p-benzyl-DOTA-trastuzumab. EJNMMI Res. 1:182011. View Article : Google Scholar
|
|
11
|
Borchardt PE, Yuan RR, Miederer M,
McDevitt MR and Scheinberg DA: Targeted Actinium-225 in vivo
generators for therapy of ovarian cancer. Cancer Res. 63:5084–5090.
2003.PubMed/NCBI
|
|
12
|
Zhang T, Shen Y, Chen Y, Hsieh JT and Kong
Z: The ATM inhibitor KU55933 sensitizes radioresistant bladder
cancer cells with DAB2IP gene defect. Int J Radiat Biol.
91:368–378. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ren R, He M, Dong C, Xie Y, Ye S, Yuan D
and Shao C: Dose response of micronuclei induced by combination of
α-particles and γ-rays in human lymphoblast cells. Mutat Res.
741–742:51–56. 2013. View Article : Google Scholar
|
|
14
|
Yang C, Zhang TT, Chen Y and Kong ZL:
Relationship between expression level of ATM and DAB2IP-knockdown
induced radio-resistance in prostate cancer cells. J Radiat Res
Radiat Process. 33:0202032015.In Chinese.
|
|
15
|
Alberti C: Prostate cancer:
Radio-resistance molecular target-related markers and foreseeable
modalities of radiosensitization. Eur Rev Med Pharmacol Sci.
18:2275–2282. 2014.PubMed/NCBI
|
|
16
|
Thompson IM, Tangen CM, Paradelo J, Lucia
MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, et
al: Adjuvant radiotherapy for pathological T3N0M0 prostate cancer
significantly reduces risk of metastases and improves survival:
Long-term followup of a randomized clinical trial. J Urol.
181:956–962. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ghisolfi L, Keates AC, Hu X, Lee DK and Li
CJ: Ionizing radiation induces stemness in cancer cells. PLoS One.
7:e436282012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jacobs C, Tumati V, Kapur P, Yan J, Hong
D, Bhuiyan M, Xie XJ, Pistenmaa D, Yu L, Hsieh JT, et al:
DOC-2/DAB2 interacting protein status in high-risk prostate cancer
correlates with outcome for patients treated with radiation
therapy. Int J Radiat Oncol Biol Phys. 89:729–735. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tomimatsu N, Mukherjee B and Burma S:
Distinct roles of ATR and DNA-PKcs in triggering DNA damage
responses in ATM-deficient cells. EMBO Rep. 10:629–635. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chaudhary MW and Al-Baradie RS:
Ataxia-telangiectasia: Future prospects. Appl Clin Genet.
7:159–167. 2014.PubMed/NCBI
|
|
21
|
Di Minin G, Bellazzo A, Dal Ferro M,
Chiaruttini G, Nuzzo S, Bicciato S, Piazza S, Rami D, Bulla R,
Sommaggio R, et al: Mutant p53 reprograms TNF signaling in cancer
cells through interaction with the tumor suppressor DAB2IP. Mol
Cell. 56:617–629. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu H, Yang W, Gao H, Jiang T, Gu B, Dong
Q, Xu W, Wu S and Sun X: Nimotuzumab abrogates acquired
radio-resistance of KYSE-150R esophageal cancer cells by inhibiting
EGFR signaling and cellular DNA repair. Onco Targets Ther.
8:509–518. 2015. View Article : Google Scholar :
|
|
23
|
Hada M and Georgakilas AG: Formation of
clustered DNA damage after high-LET irradiation: A review. J Radiat
Res. 49:203–210. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xue L, Furusawa Y, Okayasu R, Miura M, Cui
X, Liu C, Hirayama R, Matsumoto Y, Yajima H and Yu D: The
complexity of DNA double stand breaks is a curcial factor for
activating ATR signaling pathway for G2/M checkpoint regulation
regardless of ATM function. DNA Repair (Amst). 25:72–83. 2015.
View Article : Google Scholar
|
|
25
|
Xue L, Yu D, Furusawa Y, Okayasu R, Tong
J, Cao J and Fan S: Regulation of ATM in DNA double strand break
repair accounts for the radiosensitivity in human cells exposed to
high linear energy transfer ionizing radiation. Mutat Res.
670:15–23. 2009. View Article : Google Scholar : PubMed/NCBI
|
